Evidence map›Paper›PMID 27758767›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2016

2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

John H Griffin, Laurent O Mosnier, José A Fernández, Berislav V Zlokovic

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Activated protein C in neuroprotection and malaria.Current opinion in hematology · 2019
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Thrombotic Regulation From the Endothelial Cell Perspectives.Arteriosclerosis, thrombosis, and vascular biology · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

John H GriffinFrom the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (J.H.G., L.O.M., J.A.F.); Division of Hematology/Oncology, Department of Medicine, University of California, San Diego (J.H.G.); and Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles (B.V.Z.). jgriffin@scripps.edu.
Laurent O MosnierFrom the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (J.H.G., L.O.M., J.A.F.); Division of Hematology/Oncology, Department of Medicine, University of California, San Diego (J.H.G.); and Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles (B.V.Z.).
José A FernándezFrom the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (J.H.G., L.O.M., J.A.F.); Division of Hematology/Oncology, Department of Medicine, University of California, San Diego (J.H.G.); and Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles (B.V.Z.).
Berislav V ZlokovicFrom the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (J.H.G., L.O.M., J.A.F.); Division of Hematology/Oncology, Department of Medicine, University of California, San Diego (J.H.G.); and Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles (B.V.Z.).
University of California, San Diego · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRASKIE, MEREDITH NICOLE · 1985 to 2019
$41.0M
THROMBUS FORMATION IN BABOONSP01HL031950 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 1985 to 2015
$29.4M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
Structure and Function of Protein CR01HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 2005 to 2017
$9.6M
REGULATION OF BRAIN THROMBOSIS IN STROKE MODELSR01HL063290 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 1999 to 2013
$7.5M
Structure-function of cytoprotective coagulation proteases and their receptorsR01HL104165 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI MOSNIER, LAURENT OLIVIER · 2011 to 2024
$6.1M
Activated protein C system in stroke modelsR01NS090904 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2014 to 2018
$3.2M
STRUCTURE/FUNCTION OF PROTEIN CR37HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI GRIFFIN, JOHN H · 1995 to 2004
$2.9M
Discovery of novel vascular therapies targeting PfEMP1-mediated cytoadhesion in severe malariaR01HL130678 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI LAVSTSEN, THOMAS, MOSNIER, LAURENT OLIVIER · 2015 to 2018
$2.0M
NHLBI NIH HHS P01 HL031950NHLBI NIH HHS R01 HL052246NHLBI NIH HHS R01 HL063290NHLBI NIH HHS R01 HL104165NHLBI NIH HHS R01 HL130678NHLBI NIH HHS R37 HL052246NIA NIH HHS P01 AG052350NIA NIH HHS P50 AG005142NINDS NIH HHS R01 NS090904
6 · The paper itself

Abstract

APC (activated protein C), derived from the plasma protease zymogen, is antithrombotic and anti-inflammatory. In preclinical injury models, recombinant APC provides neuroprotection for multiple injuries, including ischemic stroke. APC acts directly on brain endothelial cells and neurons by initiating cell signaling that requires multiple receptors. Two or more major APC receptors mediate APC's neuroprotective cell signaling. When bound to endothelial cell protein C receptor, APC can cleave protease-activated receptor 1, causing biased cytoprotective signaling that reduces ischemia-induced injury. Pharmacological APC alleviates bleeding induced by tissue-type plasminogen activator in murine ischemic stroke studies. Remarkably, APC's signaling promotes neurogenesis. The signaling-selective recombinant variant of APC, 3K3A-APC, was engineered to lack most of the APC's anticoagulant activity but retain APC's cell signaling actions. Recombinant 3K3A-APC is in ongoing National Institutes of Health (NIH)-funded clinical trials for ischemic stroke.

Indexed as

AnimalsAntigens, CDBrainBrain IschemiaEndothelial CellsEndothelial Protein C ReceptorHemostasisHumansIntracranial ThrombosisNeurogenesisNeuronsNeuroprotective AgentsProtein CReceptor Cross-TalkReceptor, PAR-1Receptors, Cell Surface3K3A-APC proteinAntigens, CDEndothelial Protein C ReceptorNeuroprotective AgentsPROCR protein, humanProtein CReceptor, PAR-1Receptors, Cell SurfaceRecombinant Proteinsanticoagulantendothelial cellsneurogenesisneuronsstroke

Identifiers

PMID27758767
PMCPMC5119536
OpenAlexW2539582898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.